Please assess the completion status of the following clinical trial:

Trial Title: Domperidone in Refractory Gastroparesis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female~* Age 18 and older~* Symptoms or manifestations secondary to motility disorders of the upper GI tract. These include gastroparesis, functional dyspepsia, gastroesophageal reflux disease that are refractory to standard therapy.~* Patients must have a comprehensive evaluation to eliminate other causes of their symptoms. This includes a history and physical examination. A recent (within 3 years) evaluation of the upper GI tract with either upper endoscopy or upper GI radiographic series. Baseline blood tests suggested are electrolytes, magnesium, and prolactin level.~* Patient has signed informed consent for the administration of domperidone that informs the patient of potential adverse events including:~  * Increased prolactin levels~ * Breast changes~ * Extrapyramidal side effects~ * Cardiac arrhythmias including QT prolongation (increased risk with the drugs listed in the appendix)~Exclusion Criteria:~* History of, or current, arrhythmias including ventricular tachycardia, ventricular fibrillation and Torsade des Pointes. Patients with minor forms of ectopy (PACs) are not necessarily excluded.~* Clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged QTc (QTc\>450 milliseconds for males, QTc\>470 milliseconds for females)~* Clinically significant electrolyte disorders. These include significant hypokalemia, hyperkalemia, hypomagnesemia, and hypermagnesemia that cannot be corrected with treatment of these electrolyte abnormalities.~* Gastrointestinal hemorrhage or obstruction.~* Presence of a prolactinoma (prolactin-releasing pituitary tumor).~* Pregnant or breast feedings female.~* Known allergy to domperidone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Domperidone (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).